[A20-73] Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V
Last updated 16.11.2020
Project no.:
A20-73
Commission:
Commission awarded on 13.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
| Patients from 12 years of age and older with acne vulgaris of the face and/or the trunk, when many comedones, papules and pustules are present |
Result of dossier assessment:
| Added benefit not proven due to a lack of suitable study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.